Results of new meta-analysis regarding CV events in linagliptin Phase 3 trials presented at ADA
Boehringer Ingelheim and Eli Lilly and Company today announced results…
25 June 2013 | By Boehringer Ingelheim
Boehringer Ingelheim and Eli Lilly and Company today announced results from a new analysis of Phase III data demonstrating that treatment with the dipeptidyl peptidase-4 (DPP-4) inhibitor linagliptin is not associated with an increased risk of cardiovascular events in the treatment of Type 2 Diabetes (T2D), versus a number of…